The Weight Loss Breakthrough: New Drug Combo Delivers 22.7% Body Weight Loss
Meet CagriSema: When One Drug Isn't Enough
GLP‑1 drugs like semaglutide (Ozempic/Wegovy) changed the game with 15–17% average weight loss, and tirzepatide (Zepbound) pushed that to ~22% in some trials. Now we're in the combo era: stack hormones, hit more pathways, and strip off more weight.
CagriSema is a fixed‑dose weekly injection that combines:
Semaglutide 2.4 mg – a GLP‑1 receptor agonist that:
- Slows gastric emptying
- Reduces appetite
- Improves blood sugar
Cagrilintide 2.4 mg – a long‑acting amylin analogue that:
- Enhances satiety in the brain
- Suppresses appetite and food reward
- Compliments GLP‑1's gut‑brain effects
Result: two powerful satiety hormones working together instead of one.
The REDEFINE Trials: How the 22.7% Number Was Reached
CagriSema's big moment came in the REDEFINE 1 and REDEFINE 2 phase 3a trials:
- Adults with overweight or obesity (with and without type 2 diabetes)
- Once‑weekly injections for 68 weeks
- All groups also received lifestyle counseling
REDEFINE 1 (Adults Without Diabetes)
20.4% mean body weight loss with CagriSema at week 68 (treatment-policy analysis).
For people who stayed on treatment and adhered (efficacy estimand), mean weight loss climbed to 22.7%.
In comparison:
- Semaglutide 2.4 mg alone: 14.9%
- Cagrilintide alone: 11.5%
- Placebo: 3.0%
Other stats:
- 40.4% of adherent CagriSema patients lost ≥25% of body weight
- 23.1% lost ≥30% of baseline body weight
- More than half reached a BMI below 30 (moved out of the "obese" category)
REDEFINE 2 (Adults With Type 2 Diabetes)
- Average weight loss: 13.7% with CagriSema vs 3.4% with placebo at 68 weeks
- Another analysis cites 15.7% weight loss when dosing and adherence are fully accounted for
Bottom line: this combo outperformed each individual drug, placebo, and what most people can ever achieve with lifestyle alone.
How Does It Stack Up Against Other Big‑Name Drugs?
From the current data and reviews:
| Drug | Mean Weight Loss |
|---|---|
| Semaglutide (Wegovy) | ~15–17% |
| Tirzepatide (Zepbound) | up to ~22.5% |
| CagriSema | up to 22.7% (with adherence), ~20.4% (overall) |
What About Body Composition and Safety?
It's not just about raw pounds—it's what you're losing.
A prespecified body composition analysis in REDEFINE 1 reported:
- Fat mass decreased by 35.7% with CagriSema
- Lean soft tissue mass decreased by 14.4%
So like other aggressive weight‑loss drugs, CagriSema still causes substantial lean mass loss, but the majority is fat.
Expected Side Effects
Expect the same GI side effects seen with other GLP‑1–based drugs:
- Nausea and GI upset during dose titration
- Vomiting, diarrhea, constipation
- Risk of gallbladder issues
- Rare pancreatitis and other class warnings still apply
So no, this isn't magic with zero cost. It's powerful pharmacology that needs medical supervision and muscle‑preserving strategies.
Who Is CagriSema For?
Based on REDEFINE trial inclusion:
- Adults with BMI ≥30, or BMI ≥27 with at least one weight‑related comorbidity (like hypertension, dyslipidemia, sleep apnea)
- People who have failed lifestyle efforts and need pharmacologic help
- Likely to be prioritized for those with significant cardiometabolic risk, similar to current GLP‑1 criteria
Regulators will decide the final label, but expect it to follow other obesity drug indications, probably with step‑therapy or payer restrictions.
The Catch: Cost, Access, and Long‑Term Reality
When a drug hits 20–23% average weight loss, we're entering "medical bariatric surgery" territory. That means:
Financial Considerations
- Price tags will be brutal—likely similar or higher than current GLP‑1s
- Insurers will fight hard on coverage, prior authorizations, and restrictions
- Most patients will need to stay on it long‑term to maintain results, because obesity is chronic and appetite hormones rebound when drugs stop
And just like with semaglutide and tirzepatide, real‑world outcomes may underperform trial numbers due to adherence issues, side effects, dose skipping, and discontinuation.
What This Means for the Future of Obesity Treatment
CagriSema is part of a larger shift:
- From single hormones (GLP‑1) to multi‑agonist combos (GLP‑1 + amylin, GLP‑1 + GIP, GLP‑1 + glucagon)
- From 5–10% "nice to have" weight loss to 20–25%+, approaching surgical outcomes
- From "eat less, move more" sermons to targeted gut–brain hormone manipulation as front‑line therapy
This is good news if you're stuck in severe obesity with serious health risks—but it does not replace the fundamentals:
You Still Need:
- Protein to protect muscle
- Strength training and physical activity
- A real food diet to support long‑term health and maintenance
Drugs like CagriSema can make fat loss easier, faster, and more powerful—but they don't fix your environment, habits, or lifestyle for you.
The No‑BS Takeaway
A once‑weekly combination shot that can strip off up to 22.7% of your body weight is a genuine breakthrough. But it's still a tool, not a cure:
- Expect major fat loss, but also lean mass loss if you're not lifting and eating enough protein
- Expect side effects and access issues, not a magic free ride
- Expect long‑term therapy to keep the weight off
If you decide to go this route with your doctor, treat CagriSema as the engine, and your training, diet, and sleep as the steering wheel and brakes. Ignore those, and you're just crashing into a smaller version of the same wall.
Scientific References
- American Diabetes Association. "CagriSema Demonstrates Significant Weight Loss in Adults With Obesity With and Without Type 2 Diabetes." Press release, ADA 85th Scientific Sessions, 2025.
- Novo Nordisk. "CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in REDEFINE 1." Canadian press release, 2025.
- Gastroenterology Advisor. "CagriSema Elicits Significant Weight Loss in Obesity With or Without Type 2 Diabetes." 2025.
- ACC Journal Scan. "Greater Weight Loss With Combined Cagrilintide–Semaglutide vs. Either Alone: REDEFINE 1 and 2." 2025.
- PharmExec. "Novo Nordisk's CagriSema Falls Short of 25% Weight Loss Target." 2025.
- FierceBiotech. "Novo Nordisk Stock Crashes After CagriSema Misses Phase 3 Weight-Loss Goal." 2024.
- ClinicSearch. "Cagrilintide Combined with Semaglutide: A New Approach for Treatment of Obesity and Type 2 Diabetes." 2023.
- Nature Reviews Endocrinology. "What Is the Pipeline for Future Medications for Obesity?" 2024.
- Drug Discovery Trends. "Lilly's Triple Agonist Delivers Up to 71.2 lbs of Weight Loss in Phase 3 Trial." 2025.
- PubMed. "Coadministered Cagrilintide and Semaglutide in Adults With Overweight or Obesity (REDEFINE 1)." 2025.
